Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul J Declerck

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Expert Opinion on Biological Therapy|January 5, 2013
Biosimilar monoclonal antibodies: a science-based regulatory challengePaul J Declerck
Drug Safety|November 27, 2007
Biotherapeutics in the era of biosimilars: what really matters is patient safetyPaul J Declerck
Current Medicinal Chemistry|September 24, 2004
Plasminogen activator inhibitor-1Ann Gils, Paul J Declerck
Seminars in Thrombosis and Hemostasis|March 19, 2013
Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpinPaul J Declerck, Ann Gils
International Journal of Molecular Sciences|April 3, 2021
A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?Machteld Sillen, Paul J Declerck
Journal of Translational Medicine|June 9, 2017
State of play and clinical prospects of antibody gene transferKevin Hollevoet, Paul J Declerck
Frontiers in Cardiovascular Medicine|January 8, 2021
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and InhibitionMachteld Sillen, Paul J Declerck
Thrombosis and Haemostasis|February 26, 2004
The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitorsAnn Gils, Paul J Declerck
Drug Discovery Today|June 3, 2014
Novel or expanding current targets in fibrinolysisTine Wyseure, Paul J Declerck
Cell Chemical Biology|June 25, 2016
Prevention of Serpin Misfolding by RNA AptamersXiaohua Zhou, Paul J Declerck
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Expert Opinion on Biological Therapy|January 5, 2013
Biosimilar monoclonal antibodies: a science-based regulatory challengePaul J Declerck
Drug Safety|November 27, 2007
Biotherapeutics in the era of biosimilars: what really matters is patient safetyPaul J Declerck
Current Medicinal Chemistry|September 24, 2004
Plasminogen activator inhibitor-1Ann Gils, Paul J Declerck
Seminars in Thrombosis and Hemostasis|March 19, 2013
Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpinPaul J Declerck, Ann Gils
International Journal of Molecular Sciences|April 3, 2021
A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?Machteld Sillen, Paul J Declerck
Journal of Translational Medicine|June 9, 2017
State of play and clinical prospects of antibody gene transferKevin Hollevoet, Paul J Declerck
Frontiers in Cardiovascular Medicine|January 8, 2021
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and InhibitionMachteld Sillen, Paul J Declerck
Thrombosis and Haemostasis|February 26, 2004
The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitorsAnn Gils, Paul J Declerck
Drug Discovery Today|June 3, 2014
Novel or expanding current targets in fibrinolysisTine Wyseure, Paul J Declerck
Cell Chemical Biology|June 25, 2016
Prevention of Serpin Misfolding by RNA AptamersXiaohua Zhou, Paul J Declerck
Pageof 10